Evidence map›Paper›PMID 30799951›Full record

ArticleCancer management and research2019

Pretreatment detection of circulating and tissue CD133

Asmaa M Zahran, Amal Rayan, Hussein Fakhry, Alia M Attia, Ahmed M Ashmawy, Ahmed Soliman, Azza Elkady, Helal F Hetta

Abstract read
In one paragraph

Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Asmaa M ZahranDepartment of Clinical Pathology, South Egypt Cancer Institute, Assiut, Egypt.
Amal RayanDepartment of Clinical Oncology, Assiut University Hospital, Assiut University, Assiut, Egypt.
Hussein FakhryDepartment of Surgical Oncology, South Egypt Cancer Institute, Assiut, Egypt.
Alia M AttiaDepartment of Radiation Oncology, South Egypt Cancer Institute, Assiut, Egypt.
Ahmed M AshmawyDepartment of Internal Medicine, Assiut University Hospital, Assiut, Egypt.
Ahmed SolimanDepartment of General Surgery, Faculty of Medicine, Assiut University, Assiut, Egypt.
Azza ElkadySohag University Medical Administration, Sohag, Egypt.
Helal F HettaDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt, helal.hetta@uc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimColorectal cancer is one of the most common malignant tumors worldwide. As CD133 and CD44 are notable markers of cancer stem cells (CSCs) identity, it is thought to be a predictive indicator for colorectal cancer. The aim of this study was to investigate the cell cycle state of CD133 MATERIALS AND

methodsTissue samples were collected from 50 primary colorectal cancer patients. Flow cytometric analysis was performed to isolate tissue CD133

resultsHigher percentage of tissue CD133

conclusionTissue CD133

Indexed as

cancer stem cellsCD133+ CD44+colorectal cancer

Identifiers

PMID30799951
PMCPMC6369859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.